Time to Screen for Congenital Toxoplasmosis?

Open Access
Publisher Website
Google Scholar
Abstract
Although the devastating consequences of congenital toxoplasmosis are well known as part of the TORCH syndrome (i.e., toxoplasmosis, syphilis, rubella, cytomegalovirus, and herpes infections), many aspects of surveillance and treatment of congenital toxoplasmosis have remained controversial because of incomplete data regarding the prevalence of disease and the impact of treatment. McLeod et al. [1] now report the results of a longitudinal study that shows the significant impact of treatment on 120 congenitally infected children who were treated for 1 year with pyrimethamine and sulfadiazine. The National Collaborative Chicago-Based, Congenital Toxoplasmosis Study has been observing affected children prospectively since 1981 [2]. Currently, the 1-year treatment regimen is the standard of care in the United States for congenital toxoplasmosis, but the long-term impact of treatment was unknown.

This publication has 10 references indexed in Scilit: